Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

Mohammed Snober, Richard Syzdlo, PhD, Jane Apperley, MB ChB MD, Aristeidis Chaidos, MD PhD, Edward Kanfer, PhD, Dragana Milojkovic, MBBS, PhD, Eduardo Olavarria, MD PhD, Renuka Palanicawandar, MD MRCP, FRCPath, Jiri Pavlu, MD MRCP, FRCPath, Jeannie F Todd, PhD, Nina Salooja, MD

Blood (2018) 132 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2018-99-114229

Published: 2018

Journal Articles

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley, MRCP, MBBS, David Slade, Richard Syzdlo, PhD, George Nasry Nesr, MB BCh, Simone Claudiani, MD, Irene Caballes, RN, Fiona Fernando, MBChB, Jiri Pavlu, MD MRCP, FRCPath, Renuka Palani, MD, Edward Kanfer, FRCP, Eduardo Olavarria, MD PhD, Dragana Milojkovic, MBBS, PhD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 5746.

https://doi.org/10.1182/blood-2018-99-114420

Published: 2018

Journal Articles

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Mary Alikian, Rebecca Ellwood, Olga Tatarinova, Graham David Rose, George Nteliopoulos, Gareth Gerrard, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD, Alistair Reid, BSc, PhD, Letizia Foroni, MD PhD, Richard Clark, MBBS, MRCP, MRCPath, MD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2018-99-117616

Published: 2018

Journal Articles

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

Michael W. Deininger, MD PhD, Vamsi Kota, MBBS, Jeff H. Lipton, MD PhD, Dragana Milojkovic, MBBS, PhD, Valentín García Gutiérrez, PhD, Eric Leip, PhD, Sonja Nick, MSc, Andreas Hochhaus, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Tim H. Brummendorf, MD

Blood (2018) 132 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2018-99-110798

Published: 2018

Journal Articles

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Simone Claudiani, MD, Jane Apperley, MB ChB MD, Afzal Khan, Richard Szydlo, PhD, George Nesr, MD, George Adams, MBChB, Letizia Foroni, MD PhD, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2018-99-119602

Published: 2018

Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 896.

https://doi.org/10.1182/blood.V130.Suppl_1.896.896

Published: 2017

Journal Articles

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Dragana Milojkovic, MBBS, PhD, Richard E. Clark, Jennifer L Byrne, Brian J.P Huntly, Manoj Raghavan, Farooq A Wandroo, Sahra Ali, Belinda Austen, Jacqueline Ryan, Karsten Friedrich, Nicholas C.P. Cross, PhD, Adam J Mead, MD PhD

Blood (2017) 130 (Supplement 1): 2892.

https://doi.org/10.1182/blood.V130.Suppl_1.2892.2892

Published: 2017

Journal Articles

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Carla Mamolo, Arlene Reisman, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf

Blood (2017) 130 (Supplement 1): 2895.

https://doi.org/10.1182/blood.V130.Suppl_1.2895.2895

Published: 2017

Journal Articles

A Single-Cell Approach to Unraveling Abnormal Megakaryocyte Differentiation and Function in Myelofibrosis

Bethan Psaila, MD PhD, Elisabeth F Heuston, PhD, Dragana Milojkovic, MBBS, PhD, Jens Lichtenberg, Stacie M Anderson, Ronald Hoffman, MD, Irene Roberts, MD, Adam J Mead, MD PhD, David M. Bodine, PhD, NISC Comparative Sequencing Program, Nikolaos Barkas, PhD

Blood (2017) 130 (Supplement 1): 490.

https://doi.org/10.1182/blood.V130.Suppl_1.490.490

Published: 2017

Journal Articles

A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Mark W Drummond, MB ChB, PhD FRCPath, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Samuel Munoz Vicente, MSc, Adam J Mead, MD PhD, Christina Yap, MSci, PhD CStat, Frederick Chen, FRCP, FRCPath, PhD, Srinivasan Narayanan, MBBS, MRCP, FRCPath, Dragana Milojkovic, MBBS, PhD, Leyre Navarro-Nunez, PhD, Steven Knapper, BMBCh, MRCP, MRCPath, DM

Blood (2017) 130 (Supplement 1): 1649.

https://doi.org/10.1182/blood.V130.Suppl_1.1649.1649

Published: 2017

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Andreas Hochhaus, Prof. Dr., Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Timothy H. Brümmendorf, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1618.

https://doi.org/10.1182/blood.V130.Suppl_1.1618.1618

Published: 2017

Journal Articles

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

Louise Caldwell, BSc, Simone Claudiani, MD, Dragana Milojkovic, MBBS, PhD, Richard Szydlo, PhD, Elisabetta Abruzzese, MD, George Nesr, MD, Michael J. Mauro, MD, Renuka Palanicawander, MD, Aoife Gatenby, BSc, Ira Sabli, BSc, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1612.

https://doi.org/10.1182/blood.V130.Suppl_1.1612.1612

Published: 2017

Journal Articles

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Blood (2017) 130 (Supplement 1): 1620.

https://doi.org/10.1182/blood.V130.Suppl_1.1620.1620

Published: 2017

Journal Articles

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Simone Claudiani, MD, Adi Shacham Abulafia, Ira Sabli, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1628.

https://doi.org/10.1182/blood.V130.Suppl_1.1628.1628

Published: 2017

Journal Articles

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Simone Claudiani, MD, Aoife Gatenby, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, Emily Ching, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1629.

https://doi.org/10.1182/blood.V130.Suppl_1.1629.1629

Published: 2017

NARROW

Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

A Single-Cell Approach to Unraveling Abnormal Megakaryocyte Differentiation and Function in Myelofibrosis

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only